Theravance Biopharma has garnered renewed attention from analysts as the consensus price target for its stock has moved upward from $20.00 to $21.50. This reflects a fresh assessment of the company's ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.

As of November 12, 2025, ProMIS has fully enrolled Cohorts 1 and 2 and is well into Cohort 3, with complete enrollment expected before the end of the year. PMN310 continues to demonstrate a favorable ...

Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 2026 ...

Apellis Pharmaceuticals, Inc. ( APLS) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

Allergan Aesthetics, an AbbVie company , today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of ...

Read here for insights on Lineage’s cell therapy pipeline, key partnerships, and 2026 catalysts. Learn why now may be the ...

Scientists have discovered strange microscopic structures in the blood of people with Long COVID—clusters of tiny microclots ...

Biliary atresia (BA) represents one of the leading causes of pediatric liver failure, often requiring surgical intervention ...

Patients with GCA receiving combination IVMP/MTX with lower-dose prednisone had lower cumulative GC doses and fewer related side effects vs SOC.